Abstract: The present invention is directed towards methods of culturing non-keratinocyte epithelial cells, with the methods comprising culturing non-keratinocyte epithelial cells in the presence of feeder cells and a calcium-containing medium while inhibiting the activity of Rho kinase (ROCK) in the feeder cell, the non-keratinocyte epithelial cells or both during culturing.
Abstract: Provided are: a transformation plasmid for transforming anaerobes and enabling highly efficient and stable secretory expression of a target protein; a gene delivery carrier formed from said anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these. Also provided are: a novel secretory signal; a transformation plasmid including said secretory signal; a gene delivery carrier formed from anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these.
Type:
Grant
Filed:
January 18, 2016
Date of Patent:
May 4, 2021
Assignees:
Shinshu University, Anaeropharma Science, Inc.
Abstract: A pharmaceutical composition includes polymer units ? and ?, each having a hydrophilic polymer chain bound to a cationic polymer chain, and a drug. The polymer units ? and ? are radially arranged such that the cationic polymer chains are directed inward and the hydrophilic polymer chains are directed outward, thereby forming a micelle with the drug encapsulated in the micelle. The cationic polymer chain of the polymer unit ? has a phenylboronic acid group in a side chain, and the cationic polymer chain of the polymer unit ? has a phenylboronic acid binding site in a side chain. The phenylboronic acid group and the phenylboronic acid binding site form a cross-linked structure that can dissociate in an acidic environment and/or in the presence of a substance capable of competitive binding.
Type:
Grant
Filed:
May 8, 2015
Date of Patent:
May 4, 2021
Assignee:
KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION
Abstract: A device that allows for either fat graft preparation or cell fraction harvest is disclosed. The device includes a first centrifuge tube configured to receive and process a biological substance, the first centrifuge tube comprising an upper cylindrical portion and a lower conical portion, a sterile tissue inlet fitting, at least one sterile processing fluid inlet fitting, a sterile suction fitting, and at least one sterile extraction port connected to a first extraction tube. The first centrifuge tube further includes an internal space including a screen being positioned therein, the screen being configured to divide the internal space in half, and a filter positioned therein, the filter being positioned below the screen in the lower conical portion of the first centrifuge tube. The device may further include a second centrifuge tube configured to receive and further process the biological substance from the first centrifuge tube.
Abstract: A method of expanding and maintaining human embryonic stem cells (ESCs) in an undifferentiated state by culturing the ESCs in a suspension culture under culturing conditions devoid of substrate adherence is provided. Also provided are a method of deriving ESC lines in the suspension culture and methods of generating lineage-specific cells from ESCs which were expanded in the suspension culture of the present invention.
Type:
Grant
Filed:
November 16, 2017
Date of Patent:
April 6, 2021
Assignee:
Teehnion Research & Development Foundation Limited
Abstract: Embodiments of the presently disclosed subject matter provide biomimetic cell culture substrates comprising highly tunable patterned polymer nanofiber matrices capable of modulating expression of critical self-renewal factors and markers of cell-cell interaction to maintain stemness of human mesenchymal stem cells in vitro. Embodiments of the presently-disclosed subject matter also provide scalable, highly repeatable methods of making biomimetic cell culture substrates by hot pressing thermoplastic polymer films into femtosecond laser-ablated nanopore molds to form patterned polymer nanofiber matrices on flat thermoplastic substrates.
Type:
Grant
Filed:
February 3, 2016
Date of Patent:
March 9, 2021
Assignee:
Ultra Small Fibers, LLC
Inventors:
William Hudson Hofmeister, Lucas Hofmeister, Alexander Yuryevich Terekhov, Jose Lino Vasconcelos da Costa
Abstract: Chimeric antigen receptors (CARs) containing HIV envelope antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing HIV-infection in a subject, and methods of making CAR T cells are also disclosed. Results of treating or preventing HIV-infection, and results of making CAR T cells are also disclosed.
Type:
Grant
Filed:
December 20, 2018
Date of Patent:
January 19, 2021
Assignee:
LENTIGEN TECHNOLOGY, INC.
Inventors:
Kim Anthony Gonda, Dina Schneider, Rimas Orentas, Boro Dropulic
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Grant
Filed:
June 7, 2019
Date of Patent:
January 5, 2021
Assignee:
CRISPR Therapeutics AG
Inventors:
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Abstract: Provided are microvesicles isolated from milk, compositions thereof and uses for the preparation of milk formulas. Further provided are microvesicles, including exosomes and/or fat globules which encapsulate various miRNA molecules and uses thereof, as exemplified by supplementing milk formulas.
Type:
Grant
Filed:
November 29, 2016
Date of Patent:
December 29, 2020
Assignee:
Hadasit Medical Research Services and Development Ltd.
Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.
Type:
Grant
Filed:
June 6, 2019
Date of Patent:
December 8, 2020
Assignee:
CRISPR Therapeutics AG
Inventors:
Jonathan Alexander Terrett, Demetrios Kalaitzidis, Lawrence Klein
Abstract: The present invention relates to a mammalian cell comprising a gene encoding a polypeptide of interest, wherein the polypeptide of interest is expressed comprising one or more posttranslational modification patterns. These modifications are useful for example in glycoprotein production where the antibodies with the modifications have an enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). The present invention also relates to methods for producing the glycoproteins and compositions comprising the glycoproteins, and their uses.
Type:
Grant
Filed:
December 11, 2015
Date of Patent:
December 8, 2020
Assignees:
University of Copenhagen, Dansmarks Tekniske Universitet
Inventors:
Henrik Clausen, Zhang Yang, Adnan Fevzi Halim, Eric Bennett, Carsten Behrens, Malene Bech Vester-Christensen, Shamim Herbert Rahman
Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
Type:
Grant
Filed:
September 19, 2018
Date of Patent:
November 24, 2020
Assignee:
Novartis AG
Inventors:
Rohan Eric John Beckwith, Luis Brito, Brian Addison DeChristopher, Gabriel Grant Gamber, Andrew Geall, Thomas Zabawa
Abstract: A new simple transfection method using an integrated electrowetting nano-injector (“INENI”) with controlled dosage delivery and high transfection efficiency is disclosed. The volume of delivery can be controlled via voltage application to an inner and outer electrode integrated into a nano-pipette. With higher voltages, more liquid enters the INENI and with lower voltages liquid is expelled. This method can be used to deliver plasmid DNA directly into the nuclei of cells. The INENI requires only the use of a single probe since both electrodes are integrated into the same nano-pipette. Hence, more space is available, and ergo the INENI offers a simplistic means for direct injection of metered amounts of exogenous material into the confines of a cell cytoplasm and/or nucleus while retaining full cell viability.
Type:
Grant
Filed:
June 19, 2018
Date of Patent:
November 24, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Hemantha K. Wickramasinghe, Elaheh Shekaramiz
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Type:
Grant
Filed:
December 1, 2017
Date of Patent:
November 17, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Wendell A. Lim, Leonardo Morsut, Kole T. Roybal, Satoshi Toda, Justin Thomas Farlow
Abstract: The present disclosure provides binding-triggered transcriptional switch polypeptides, nucleic acids comprising nucleotide sequences encoding the binding-triggered transcriptional switch polypeptides, and host cells genetically modified with the nucleic acids. The present disclosure also provides chimeric Notch receptor polypeptides, nucleic acids comprising nucleotide sequences encoding the chimeric Notch receptor polypeptides, and host cells transduced and/or genetically modified with the nucleic acids. The present disclosure provides transgenic organisms comprising a nucleic acid encoding a binding triggered transcriptional switch polypeptide and/or a chimeric Notch receptor polypeptide of the present disclosure. Binding triggered transcriptional switch polypeptides and chimeric Notch receptor polypeptides of the present disclosure are useful in a variety of applications, which are also provided.
Type:
Grant
Filed:
December 4, 2017
Date of Patent:
November 3, 2020
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Wendell A. Lim, Leonardo Morsut, Kole T. Roybal
Abstract: The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
Type:
Grant
Filed:
July 28, 2018
Date of Patent:
November 3, 2020
Assignee:
AQUESTIVE THERAPEUTICS, INC.
Inventors:
Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, B. Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
Type:
Grant
Filed:
September 26, 2019
Date of Patent:
November 3, 2020
Assignee:
LENTIGEN TECHNOLOGY, INC.
Inventors:
Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
Abstract: This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.
Type:
Grant
Filed:
August 29, 2018
Date of Patent:
October 6, 2020
Assignee:
NOVARTIS AG
Inventors:
Jeremy Lee Baryza, Rohan Eric John Beckwith, Keith Bowman, Crystal Byers, Tanzina Fazal, Gabriel Grant Gamber, Cameron Chuck-Munn Lee, Ritesh Bhanudasji Tichkule, Chandra Vargeese, Shuangxi Wang, Laura West, Thomas Zabawa, Junping Zhao
Abstract: A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or unsubstituted alkyl group, an alkenyl group, an acyl group, or an aromatic group, or includes a polymer, a targeting group, or a detectable moiety, and at least one of R4 and R5 includes a targeting group that targets and/or binds to a retinal or visual protein; a, b, c, and d are independently an integer from 1 to 10; and pharmaceutically acceptable salts thereof.
Abstract: Various embodiments disclosed relate to a nanoparticle-protein complex for intracellular protein delivery. In various embodiments, the present invention provides a nanoparticle-protein complex including a nanoparticle including an amine-containing ligand. The nanoparticle-protein complex also includes a protein comprising a carboxylic acid-containing tag.